Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels
Primary result · MACE (composite of cardiovascular death, myocardial infarction, or stroke)Result — go to the resultHazard ratio 1.40 95% CI 1.21–1.63Authors' conclusion
Baseline elevated NLR predicts MACE in post-AMI patients, and CSL112 showed an associated reduction in MACE in patients with elevated NLR and LDL-C ≥100 mg/dL.
Study context
- Population
- Participants with acute myocardial infarction (AMI), multivessel coronary artery disease, and additional cardiovascular risk factorsrandomized, 15,966 participants in the analysis
- Participants
- 18,219 participants
- Comparison
- Neutrophil-lymphocyte ratio (NLR) >median vs NLR ≤median
- Primary endpoint
- MACE:
- Cardiovascular death
- Myocardial infarction
- Stroke
- Follow-up
- 90 days
Methodological detailsrandomized to 4 weekly infusions of 6 g CSL112 or placebo
- Randomized to 4 weekly infusions of 6 g CSL112 or placebo
Primary result
As reported in the abstract
Hazard ratio
1.40
95% CI 1.21–1.63
NLR >median vs NLR ≤median
HR 1.40 (95% CI 1.21–1.63)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| MACE among participants with elevated NLR and LDL-C ≥100 mg/dL · 90 daysCSL112 vs placebo · sustained benefits at 180 and 365 days | 0.63 (0.42–0.93) | |
| 0.512Hazard ratio (log scale) |
Treatment interactions · 180 days
- Interaction between treatment and NLR
- P for interaction = 0.010
- Interaction among treatment, NLR, and low-density lipoprotein cholesterol (LDL-C) at 180 days
- P for interaction = 0.029
Original publication
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels. JACC Adv. Published 29 March 2025. doi:10.
Summarised from the published abstract; every number is checked against it